Evommune (EVMN) Cash & Current Investments (2024 - 2026)

Evommune (EVMN) has 3 years of Cash & Current Investments data on file, last reported at $211.5 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 3607.29% year-over-year to $211.5 million in Q1 2026; TTM through Mar 2026 was $211.5 million, a 3607.29% increase from a year earlier, with the FY2025 full-year figure at $149.2 million, up 107.11% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $211.5 million, up from $149.2 million in the prior quarter.
• Over the last five years, Cash & Current Investments for EVMN reached as high as $211.5 million in Q1 2026 and fell as low as $5.7 million in Q1 2025.
• Historically, Cash & Current Investments has averaged $88.8 million across 3 years, with a median of $74.1 million in 2024.
• Across the five-year window, Cash & Current Investments jumped 107.11% in 2025 and soared 3607.29% in 2026, its largest moves.
• Year by year, Cash & Current Investments stood at $72.0 million in 2024, then soared by 107.11% to $149.2 million in 2025, then jumped by 41.73% to $211.5 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $211.5 million in Q1 2026, $149.2 million in Q4 2025, and $76.1 million in Q3 2025.